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OBJECTIVES We compared the predictive properties of P-selectin to creatine kinase, MB fraction
(CK-MB) for detecting acute myocardial infarction (AMI), acute coronary syndromes (ACS)
and serious cardiac events upon emergency department (ED) arrival.
BACKGROUND Practioners detecting early diagnosis of ACS have focused on cardiac markers of myocardial
injury. Plaque rupture/platelet aggregation precedes myocardial ischemia. Therefore, markers
of platelet aggregation may detect ACS earlier than cardiac markers.
METHODS Consecutive patients with potential ACS presenting to an urban university ED were
identified by research assistants who screened all ED patients between November 12, 1997
and January 31, 1998. Whole blood was drawn at presentation and 1 h later and rapidly
stained and fixed for membrane P-selectin assay and plasma was separated for soluble
P-selectin assay. Creatine kinase, MB fraction values were determined using standard
immunoassay techniques. Clinical history and hospital course were followed daily. Outcomes
were AMI, ACS (AMI and unstable angina) and serious cardiac events. Receiver operator
characteristic curves were derived for CK-MB, and soluble and membrane-bound P-selectin
to determine the optimal cutoff values. Predictive properties were calculated with 95%
confidence intervals.
RESULTS A total of 263 patients were enrolled. They had a mean age of 56.5 6 14 years; 52% were
male. There were 22 patients with AMI; 87 patients with ACS and 54 patients with serious
cardiac events. Creatine kinase, MB fraction had a higher specificity for detection of AMI,
ACS and serious cardiac events than both soluble and membrane-bound P-selectin. At the
time of ED presentation, the specificity of CK-MB, and soluble and membrane-bound
P-selectin for AMI was 91% versus 76% versus 71%; for ACS, 95% versus 79% versus 71%,
and for serious cardiac events, 91% versus 76% versus 72% (p , 0.05). The sensitivities for
AMI were 50% versus 45% versus 32%; for ACS, 26% versus 35% versus 30%, and for serious
cardiac events, 29% versus 35% versus 36%.
CONCLUSIONS Although theoretically attractive, the use of soluble and membrane-bound P-selectin for risk
stratification of chest pain patients at the time of ED presentation does not appear to have any
advantages over the use of CK-MB. (J Am Coll Cardiol 1999;34:95–105) © 1999 by the
American College of Cardiology
There are more than five million emergency department
(ED) visits for evaluation of symptoms of acute coronary
syndromes (ACS) annually in the United States (1). Be-
cause the accuracy of the initial working diagnosis is low and
the reliability of early exclusion of ACS is uncertain, most
patients with symptoms suggestive of ACS are admitted to
expensive monitored settings or observation units for further
evaluation, placing a heavy burden on health care econom-
ics. As a result, several strategies to delineate the patients’
initial risk have been developed and tested. Although several
clinical and computer algorithms have been able to stratify
patients into low and high risk groups for infarction or
cardiovascular complications, these algorithms have not
identified a group of patients at such low risk that they can
be safely and immediately released from the ED (2–8).
Consequently, recent research has focused on the use of
adjunctive technologies to stratify patients into high and low
risk groups for infarction and other cardiovascular compli-
cations. These strategies include serial electrocardiograms,
continuous ST-segment monitoring (9,10), additional elec-
trocardiographic leads (11–13), marker proteins of myocar-
dial injury, such as creatine kinase, MB fraction (CK-MB)
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(14–20), myoglobin (21–25) and the cardiac troponins
(26–30) and the use of short-term observation units (31–
34). Despite intensive investigation, these strategies, which
largely focus on identification of patients with myocardial
injury, have not identified patients at such low risk that they
can be safely released from the ED. An alternative strategy,
identification of patients with ACS before the commence-
ment of myocardial injury, is appealing. In theory, detection
of platelet activation could identify high risk patients before
the occurrence of myocardial injury.
A soluble form of P-selectin recently identified in the
plasma of normal individuals is an indicator of platelet
activation. It is elevated in the plasma of patients with acute
myocardial infarction (AMI) (35), unstable angina (36) and
acute lung injury (37). This molecule appears to represent
both a proteolytic fragment of membrane-bound P-selectin
and a soluble splice variant lacking the transmembrane
domain of P-selectin (38). Preliminary data suggest that
flow cytometric determination of transmembrane P-selectin
expression as a marker of platelet activation may differen-
tiate stable from unstable coronary artery disease (39). The
purpose of the present study was to evaluate the predictive
properties of soluble and membrane-bound P-selectin for
the ED risk stratification of patients with ACS.
METHODS
Study design. We performed a prospective observational
clinical study to evaluate the sensitivity and specificity of
P-selectin for the diagnosis of ACS (myocardial infarction
and unstable angina) in patients who presented to the ED
with chest pain symptoms consistent with myocardial isch-
emia.
Setting. This study was conducted in the ED of Philadel-
phia’s Hospital of the University of Pennsylvania, an urban
tertiary care center with an annual patient census of approx-
imately 47,000 visits.
Participants. Consecutive patients greater than 18 years of
age who presented to the ED between November 10, 1997
and January 31, 1998 with a chief complaint of chest pain of
less than 6 h duration consistent with acute myocardial
ischemia were eligible for inclusion. During the study
period, dedicated research assistants were present in the ED
24 h per day, 7 days per week to identify potential study
patients.
A full-time board-certified/board-eligible emergency
physician treated patients who consented to enrollment
alone or in conjunction with house staff. Patients were
excluded if they had symptoms that were clearly not cardiac
in origin (e.g., chest pain secondary to herpes zoster or
recent trauma). All study subjects provided written in-
formed consent. The study was approved by the University
of Pennsylvania Committee on Research Involving Human
Subjects.
Measurements. Patients had a structured history and
physical examination performed at the time of ED presen-
tation. Patients had study blood specimens obtained at the
time of presentation and 1 h later. These times were chosen
because serial sampling at these early times might influence
decision making and triage. Patient disposition was deter-
mined by the ED attending physician, blinded to study
sample results.
Admitted patients were followed daily throughout their
hospital course by one of the investigators. Patients were
contacted 30 days after presentation for follow-up.
Platelet P-selectin flow cytometry assay. Membrane
P-selectin expression on platelets was determined by two-
color flow cytometry of fluorophor-conjugated antibody
stained and fixed whole blood samples using the Centocor
P-Selectin FLOW Assay (Malvern, Pennsylvania). For each
patient at each time point, a 4.5-ml blood sample was drawn
into an Diatube-H (C.T.A.D.) Vacutainer evacuated anti-
coagulant tube (Becton Dickinson, ref. 367015, Investiga-
tional Use Only), through a 19-ga or larger needle. The
sample was immediately diluted 1:10 in Tyrodes’ buffer by
transferring 50 ml of whole blood to an Eppendorf tube
containing 450 ml of diluent. The tube was inverted gently
to mix. Forty microliters of reagents A (buffer only), B
(fluorescein isothiocyanate [FITC]-conjugated isotype con-
trol plus phycoerythrin (PE)-labeled pan-platelet monoclo-
nal antibody) and C (FITC-conjugated P-selectin mono-
clonal antibody S12 plus PE-labeled pan-platelet
monoclonal antibody) was added to the bottom of appro-
priately labeled amber Eppendorf tubes. Sixty microliters of
diluted whole blood were added to each of the reagent
tubes. Blood was incubated in the reagent tubes at 18 to
25°C for 15 min. After staining, an equal volume of freshly
made 2% paraformaldehyde solution was added to the
bottom of each amber reaction tube to fix the cells (final
concentration of paraformaldehyde concentration, 1%).
Samples were fixed for 30 to 120 min at room temperature.
Samples were stored refrigerated for up to 72 h before flow
cytometry without loss of fluorescence intensity. At the start
of each flow cytometric analysis, the performance of the
Becton-Dickinson FACScan and FACSSCalibur flow cy-
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tometers were standardized by running flow cytometer
control beads including Quantum 24 beads, Full Spectrum
Microbeads and Calibrite Beads. Any changes in the mean
channel fluorescence observed with the control beads re-
sulted in restandardization of the instrument to assure that
there was uniformity during the course of the study in the
detection of the percent of platelets that were positive for
P-selectin. In addition, samples were prepared using
matched FITC- and PE-labeled antibodies to check the
compensation settings used. For each clinical sample, the
unstained sample was used to check for autofluorescence of
the patient’s platelets. The stained samples were gated on
the PE-positive population (red) that was platelets. The
P-selectin–specific FTIC-conjugated (green) antibody flu-
orescence was used to determine the percent of platelets in
the clinical sample that were positive for expression of
P-selectin. Histogram overlays of the isotype control and
P-selectin–specific antibody stained samples were created
and a statistical marker was set at 1 6 0.1% gated events for
the isotype control antibody. The resulting percent positiv-
ity for the P-selectin–specific antibody samples using that
same marker is reported as P-selectin percent positive. The
integrity of the reagents was determined by the use of the
matched lot of the Centocor Diagnostics P-selectin com-
pensation kit along with the complementary Centocor
Diagnostics P-selectin flow cytometry test kit. As part of the
compensation test, the intensity of the FITC-labeled
P-selectin was determined by binding to platelets activated
with adenosine diphosphate (ADP). The integrity of the
PE-labeled pan-platelet monoclonal antibody was deter-
mined by binding to platelets in diluted whole blood.
Soluble P-selectin enzyme-linked immunosorbent assay
(EIA) assay. Within 60 min from the time it was drawn,
the remainder of the 4.5-ml blood sample was centrifuged at
1,800 g at room temperature for 15 min to make platelet-
poor plasma. The clear platelet-poor plasma was separated
from the underlying cell pellet, aliquotted and frozen at
#70°C. The levels of soluble P-selectin were determined in
the plasma using the Centocor Soluble P-Selectin EIA.
Platelet-poor plasma was prediluted 1:20 with assay buffer.
Fifty microliters of prediluted samples were run on each
EIA plate in duplicate along with triplicate 50-ml samples of
each of five standards of known soluble P-selectin value
from 0 to 45 ng/ml (multiplied by the dilution factor of 20,
the standard curve covers soluble P-selectin values up to 900
ng/ml). Plasma control samples with known values of
soluble P-selectin considered high (500 ng/ml) and low
(100 ng/ml) were run in triplicate on each plate. If the
control samples did not fall within a predetermined range of
values, the assay was considered invalid and was repeated.
Briefly, standards, control or study plasma samples, di-
luent, biotinylated P-selectin–specific monoclonal antibody
W40 and horseradish peroxidase–conjugated P-selectin–
specific monoclonal antibody S12 were added to a
streptavidin-coated microplate. The plate was incubated at
room temperature for 3 h. After the plate was washed,
3,39,5,59-tetramethylbenzidine substrate solution was added
and incubated at room temperature for 30 min. Stop
solution was added to stop color development. The plate
was read on a microplate reader using optical density 450 to
650. A standard curve was created using a four-parameter
fit; mean absorbances of the unknowns were used to
determine their P-selectin levels. Samples containing
greater than 850 ng/ml were prediluted 1:100 and were
reevaluated in the Centocor Soluble P-Selectin EIA.
Creatine kinase, MB fraction assay. Creatine kinase, MB
fraction was analyzed on the Dade Stratus immunoassay
analyzer (Dade International, Miami, Florida) utilizing a
rapid two-site sandwich monoclonal assay. This assay mea-
sures immunologic activity rather than enzymatic activity.
The within-run coefficient of variation ranges from 2.5% to
3.8% and the between-run coefficient of variation ranges
between 3.0% and 3.7%. The manufacturer defined the
reference range for CK-MB as less than 5 ng/dl.
Electrocardiogram interpretation. Electrocardiograms
(ECGs) were interpreted blinded to the patients’ serum
results and clinical outcome. Each ECG was classified into
one of seven categories using a closed question format (40):
1) normal (no electrocardiographic evidence of ischemia); 2)
nonspecific (accepted deviation from the norm with the
lowest likelihood of ischemia such as an abnormal T-wave
axis in lead III or sinus tachycardia); 3) early repolarization
variant (elevated takeoff of the ST segment at the J point of
the QRS complex greater than 1 mm relative to the
isoelectric line, downward concavity of the ST segment and
symmetrically peaked T waves often of large amplitude); 4)
abnormal but nondiagnostic of myocardial ischemia (pro-
longed QRS, corrected QT intervals, bundle branch blocks,
left ventricular hypertrophy with strain); 5) ischemia or prior
infarction known to be old (ST depression more than 0.1
mV measured 80 ms from the J point, inverted T waves
more than 0.3 mV or Q waves at least 30 ms in duration);
6) ischemia or prior infarction not known to be old, or 7)
suggestive of AMI (ST elevation greater than 0.1 mV
measured 80 ms from the J point in two or more contiguous
leads, with or without reciprocal ST depressions).
Main outcomes. The final diagnosis of myocardial infarc-
tion was based on the clinical presentation, serial ECGs and
serial in-hospital biochemical marker analysis in the hospital
clinical laboratory using World Health Organization criteria
(41). The biochemical profile diagnostic of AMI consists of
a typical rise and fall of total CK above twice normal values
within 24 h of presentation and CK-MB higher than twice
normal values.
Unstable angina was classified according to the AHCPR
risk stratification scheme (42). Because the definition of
unstable angina in the guidelines is based on the accurate
distinction of unstable angina from nonischemic chest pain
syndromes, we required demonstration of underlying coro-
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nary artery disease (.70% stenosis), exercise-induced isch-
emia (.1.5 mm ST segment depression or reversible defects
on nuclear images or echocardiography) or CK-MB detec-
tion above the upper limits of normal (5 ng/dl) but below
the threshold for AMI (5 to 10 ng/dl) to be classified as
angina.
Chest pain syndromes were considered to be nonischemic
if the patients received diagnostic testing (stress testing or
cardiac catheterization) without detection of underlying
disease. Patients who did not receive an evaluation for
underlying coronary artery disease were classified as possibly
ischemic, since ischemia was not “ruled out.”
The composite end point of serious cardiovascular events
was defined as death within 30 days from a cardiac etiology,
AMI arrhythmias requiring intervention, congestive heart
failure, hypotension requiring treatment, respiratory failure
requiring intubation, angioplasty, coronary artery bypass
surgery or cardiac arrest.
Statistical analysis. Data were entered into a Microsoft
Access 95 database (Microsoft, Redmond, Washington)
and were imported into SAS 6.12 (SAS Institute, Cary,
North Carolina) for statistical analysis. Continuous data are
presented as means with standard deviations. Categorical
data are presented as the percent frequency occurrence.
Because patients with the final diagnosis of possibly isch-
emic had similar profiles and outcomes to the patients
classified as nonischemic, and the decision to forego an
evaluation in the possibly ischemic group was based upon a
low clinical index of suspicion, these groups were combined
for analysis. Receiver operator characteristic (ROC) curves
were constructed to determine the best cutoff values for
P-selectin for each of the main outcomes (AMI, ACS and
serious cardiac events). Area under the curve was calculated
for each test and outcome and a z test was used to evaluate
the differences between two ROC curves (True Epistat 3.0,
Tracy Gustafson, Epistat S Services). Using the “best”
cutoff value for CK-MB, and soluble and membrane-bound
P-selectin, the sensitivity, specificity and positive and neg-
ative predictive values of these tests to predict AMI, ACS
and serious cardiac events were calculated with 95% confi-
dence intervals (43). Predictive properties were also pro-
vided for the combination of soluble and membrane-bound
P-selectin (the P-selectin index) and the combination of the
P-selectin index and CK-MB, requiring elevation in one or
more of these values.
RESULTS
During the 10-week study period, 293 patients with poten-
tial ACS presented to the ED. Thirty patients were ex-
cluded from participation in the study: 25 refused partici-
pation, 4 were unable to have blood samples obtained in a
timely manner and 1 patient was missed by research
assistants. As a result, the final study group was 263
patients. Comparison of patients included and excluded
from the study showed that they were similar with respect to
age, chief complaint, chest pain characteristics, cardiac risk
factors, ED diagnostic impression, triage disposition and
initial ECG.
Study patients had a mean (6 SD) age of 56.5 6 14.2
years; 52% were male. Patients presented a median of 3 h
(IQR, 60 min to 240 min) after symptom onset and the
total duration of symptoms was a median of 60 min
(interquartile range, 25 min to 180 min). The most com-
mon chief complaints were chest pain (76%) and shortness
of breath (11%). Forty-four percent of patients had multiple
symptomatic episodes within 48 h of presentation and
symptoms occurred at rest in 74%. Chest pain characteris-
tics, associated symptoms and medical history are shown in
Table 1.
The initial ECGs were classified as follows: normal, 17%;
nonspecific, 33%; early repolarization, 5%; abnormal but not
diagnostic, 21%; ischemia known to be old, 10%; ischemia
not known to be old, 10% and suggestive of AMI, 4%.
Two hundred thirty patients were admitted to the hos-
pital (cardiac care unit, 10%; cardiac intermediate care unit,
Table 1. Presenting Characteristics of Study Patients
Patient Characteristics % (n 5 263)
Chest pain characteristics
Pressure/tightness 44%
Sharp/stabbing 19%
Burning/aching 10%
Other/unknown 6%
None 13%
Chest pain location
Substernal 44%
Left chest 31%
Right chest 3%
Epigastric 6%
Other/unknown 4%
Associated symptoms
Diaphoresis 32%
Nausea 31%
Vomiting 14%
Shortness of breath 59%
Lightheadedness 23%
Syncope 4%
Palpitations 20%
Cardiac risk factors
Hypertension 69%
Diabetes mellitus 24%
Family history 22%
Elevated cholesterol 26%
Tobacco 60%
Cocaine use 5%
Past medical history
Myocardial infarction 31%
Angina 36%
Congestive heart failure 16%
CABG 9%
CABG 5 coronary artery bypass graft.
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19%; non–intensive care unit monitored bed, 57%, unmoni-
tored bed, 2%), 6 patients (2%) underwent prolonged ED
observation and 27 patients (10%) were discharged to home.
The study institution did not have an ED observation unit.
There were 22 patients with AMI (8%), 65 patients classi-
fied as unstable angina (25%), 113 patients (43%) with a
final diagnosis of nonischemic chest pain syndrome and 59
patients (22%) classified as possibly ischemic (they did not
receive a sufficient workup to “rule in” or “rule out” coronary
artery disease).
There were serious cardiac events in 54 patients, includ-
ing the 22 patients with AMI. Cardiovascular complications
that occurred after ED arrival included the following:
congestive heart failure, 8 patients (3.1%); ventricular tachy-
cardia/fibrillation, 3 patients (1.2%); supraventricular tachy-
cardia, 8 patients (3.1%); bradydysrhythmias, 3 patients
(1.2%); hypotension requiring pressors, 3 patients (1.2%),
and permanent pacemaker placement in 4 patients (1.6%).
There were three deaths during index hospitalization.
Forty-five patients had cardiac catheterization performed,
32 had coronary artery disease. Of these, 15 patients had
angioplasty and 10 patients had stent placement during
index hospitalization. One patient had coronary artery
bypass surgery. Seventy-three patients had stress testing
performed. Fifteen showed reversible ischemia.
Thirty-day follow-up was completed in 251 of the 263
patients (95%). There were 12 deaths (5%), 1 nonfatal
AMI, 4 patients who had angioplasty and 3 patients who
had stent placement after index hospitalization.
Receiver operator characteristic curves for membrane-
bound P-selectin, soluble P-selectin and CK-MB at the
time of ED presentation are shown for each of the outcomes
in Figures 1 to 3. Figure 1 shows the ROC curves for the
diagnosis of AMI. The area under the curve for CK-MB is
0.721; membrane-bound P-selectin is 0.531 and soluble
P-selectin is 0.646 (p , 0.0001 for CK-MB vs. membrane-
bound P-selectin; p 5 0.086 for CK-MB vs. soluble
P-selectin). Figure 2 shows the ROC curves for the diag-
nosis of ACS (the 87 patients with either AMI or unstable
angina). The area under the curve for CK-MB is 0.670;
membrane-bound P-selectin is 0.555 and soluble P-selectin
is 0.583 (p 5 0.003 for CK-MB vs. membrane-bound
P-selectin; p 5 0.01 for CK-MB vs. soluble P-selectin).
Figure 3 shows the ROC curves for serious cardiac events.
The area under the curve for CK-MB is 0.587, for
membrane-bound P-selectin is 0.554 and for soluble
P-selectin is 0.539 (p 5 0.233 for CK-MB vs. membrane-
bound P-selectin; p 5 0.236 for CK-MB vs. soluble
P-selectin).
Using the optimal cutoff values for each assay, as derived
from the ROC curves, the sensitivity, specificity and posi-
tive and negative predictive values along with 95% confi-
dence intervals are shown in Tables 2 to 4. Creatine kinase,
MB fraction was more specific than soluble or membrane-
bound P-selectin for the detection of AMI, ACS and
serious cardiac events. The sensitivities of the three assays
were similar.
For the detection of AMI at the time of ED presentation,
the use of a P-selectin index (requiring elevation in either
soluble or membrane-bound P-selectin) improved the sen-
sitivity at the cost of decreased specificity relative to either
P-selectin assay alone (Table 2). It did not attain greater
Figure 1. Receiver operator characteristic curves for the diagnosis of acute myocardial infarction. CK MB 5 creatine kinase, MB fraction.
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sensitivity than CK-MB. The specificity of the P-selectin
index was less than CK-MB for detection of AMI. The
addition of CK-MB to the P-selectin index did not improve
the predictive properties compared with the P-selectin index
alone.
For detection of ACS and serious cardiac events, the
P-selectin index had a higher sensitivity and lower specific-
ity than CK-MB. The positive predictive value of the
P-selectin index was less than CK-MB and the negative
predictive value was similar (Tables 3 and 4). The addition
of CK-MB to the P-selectin index did not improve the
predictive properties compared with the P-selectin index alone.
The addition of serial sampling 1 h after presentation did
not significantly affect the sensitivity, specificity and positive
Figure 2. Receiver operator characteristic curves for the diagnosis of acute coronary syndromes. CK MB 5 creatine kinase, MB fraction.
Figure 3. Receiver operator characteristic curves for the diagnosis of serious cardiac events. CK MB 5 creatine kinase, MB fraction.
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and negative predictive values of either soluble or membrane-
bound P-selectin. Patients who presented early were similar to
patients who presented later.
DISCUSSION
Acute Q-wave myocardial infarction, non–Q-wave myocar-
dial infarction and unstable angina represent the continuum
of ACS. Whereas Q-wave AMI results from an occlusive
thrombus (44), non–Q-wave myocardial infarction and
unstable angina result from subtotal thrombotic obstruction
of the coronary arteries (45). Early identification of patients
with acute ischemic syndromes has largely focused on
markers of myocardial cell injury, such as CK-MB, myo-
globin and the cardiac troponins (14–30). Although many
of these markers have independent predictive value for
cardiovascular complications, they have not been widely
used to identify patients at such low risk that they may be
discharged from the ED.
Recent treatment algorithms for patients with ACS focus
on platelet aggregation and thrombosis. After injury to the
vessel wall, atherosclerotic plaques rupture, and platelet
activation, adherence and aggregation occur (46). Acute
coronary syndromes involve a complex cascade of interac-
tions between platelets and the vascular endothelium. Log-
ically, identification of patients with ACS by detection of
platelet activation could lead to diagnosis before electrocar-
diographic or serologic evidence of myocardial ischemia. A
reliable marker of platelet activation could maximize the
benefits of early treatment through early diagnosis of myo-
cardial ischemia.
Theoretical advantages of P-selectin. P-selectin, a 140-
kDa integral membrane glycoprotein, mediates early leuko-
cyte rolling during the acute inflammatory response. It is
stored in the alpha granules of platelets and Weibel-Palade
bodies of endothelium (47,48). P-selectin is rapidly ex-
pressed at the cell surface and cleaved into the circulation
when these granules fuse with the cell surface after activa-
tion by agonists (such as thrombin and ADP). The soluble
form of P-selectin represents both a proteolytic fragment of
membrane-bound P-selectin cleaved from the surface of
Table 2. Predictive Properties of Creatine Kinase, MB Fraction (CK-MB) and P-Selectin for
Acute Myocardial Infarction At Time of Presentation
Assay Sensitivity Specificity
Positive
Predictive Value
Negative
Predictive Value
CK-MB 50% 91% 35% 95%
(31%–73%) (87%–95%) (20%–54%) (92%–98%)
Soluble P-selectin 45% 76% 15% 94%
(27%–69%) (70%–81%) (7%–24%) (91%–97%)
Membrane-bound
P-selectin
32% 71% 9% 92%
(15%–54%) (65%–77%) (3%–17%) (88%–96%)
P-selectin index (PSI) 59% 54% 11% 94%
(41%–82%) (48%–61%) (6%–16%) (90%–98%)
CK-MB and PSI 59% 54% 11% 94%
(41%–82%) (48%–61%) (6%–16%) (90%–98%)
The laboratory values were considered elevated for CK-MB $3.2 ng/dl, soluble P-selectin $138.8 ng/ml and membrane-bound
P-selectin $4.8%. These values were derived from receiver operator characteristic curve analysis at the time of presentation.
Numbers in parentheses are 95% confidence intervals.
Table 3. Predictive Properties of Creatine Kinase, MB Fraction (CK-MB) and P-Selectin for
Acute Coronary Syndrome At Time of Presentation
Assay Sensitivity Specificity
Positive
Predictive Value
Negative
Predictive Value
CK-MB 26% 95% 74% 68%
(18%–36%) (91%–99%) (60%–91%) (62%–75%)
Soluble P-selectin 35% 79% 44% 71%
(25%–46%) (72%–85%) (33%–57%) (65%–78%)
Membrane-bound
P-selectin
30% 71% 33% 68%
(21%–41%) (64%–78%) (23%–45%) (61%–75%)
P-selectin index (PSI) 55% 57% 39% 72%
(45%–66%) (50%–65%) (31%–48%) (65%–80%)
CK-MB and PSI 55% 57% 39% 72%
(45%–66%) (50%–65%) (31%–48%) (65%–80%)
The laboratory values were considered elevated for CK-MB $3.2 ng/dl, soluble P-selectin $138.8 ng/ml and membrane-bound
P-selectin $4.8%. These values were derived from receiver operator characteristic curve analysis at the time of presentation.
Numbers in parentheses are 95% confidence intervals.
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circulating activated platelets (49) and also a soluble splice
variant lacking the transmembrane domain of P-selectin
(38).
Among the markers of platelet activation, P-selectin has
significant advantages over the other markers for which
assays exist. The most obvious advantage of P-selectin is
that it can be measured in either of two forms, on the
platelet surface, or in platelet-poor plasma. Simultaneous
measurement of both membrane-bound and soluble
P-selectin (P-selectin profile) is designed to increase the
diagnostic window for this analyte around a platelet-
activating event. P-selectin molecules on the surface of
platelets are increased from 200 to 300 on an unactivated
platelet to 8,000 to 12,000 on a fully activated platelet
within minutes of exposure to platelet agonists such as
thrombin, tartrate-resistant acid phosphatase, collagen,
ADP and shear. Membrane P-selectin is detected by two-
color flow cytometry using fluorescently tagged P-selectin–
specific and pan-platelet antibodies. The soluble form of
P-selectin is readily assessed in a sandwich EIA format.
Among the other proteins released in association with
platelet activation, beta-thromboglobulin (bTG) and plate-
let factor 4 (PF4) have been used for the early diagnosis of
some thrombotic events. P-selectin has several advantages
over these proteins. First, plasma P-selectin has a longer
half-life than BTG and is not subject to ex vivo release
caused by the method of phlebotomy, as is BTG (50).
Although PF4 is only elevated in acute clinical states, its
diagnostic utility is limited by its clearance within 5 min of
release through binding to circulating glycosaminoglycans
(such as heparin) as well as those associated with the
vascular endothelium (51). This results in a very narrow
diagnostic window for PF4 and makes it not useful in
patients on heparin. Serotonin is released by activated
platelets but is assayed by a rather time-consuming radio-
immunoassay. Thromboxane A2 and B2 are produced by
the metabolism of arachidonic acid and therefore cannot be
measured accurately in the presence of aspirin-containing
medications, which inhibit arachidonic acid metabolism. In
contrast, P-selectin is stable in plasma, and less sensitive to
blood collection artifacts than these other markers of platelet
activation. In addition, the presence of heparin or traditional
doses of aspirin does not affect P-selectin (52,53).
Prior studies. In a soluble P-selectin EIA developed by
Centocor Diagnostics, a mean of 100 ng/ml 6 27.7 was
reported for 200 apparently healthy control subjects. Soluble
P-selectin levels up to 800 ng/ml have been recorded using
this EIA for patients suffering from thrombotic disorders.
Ikeda et al. found that plasma concentrations of soluble
P-selectin were higher in nine patients with AMI than in a
control cohort of 10 healthy volunteers. These samples were
obtained during the first 3 days of hospitalization (36). In a
study of 12 patients with unstable angina, 11 patients with
stable exertional angina and 15 healthy volunteers, Ikeda et
al. found that plasma P-selectin levels were elevated in the
cohort of patients with unstable angina at 1 and 3 h but not
5 h after symptom onset (35). Although the patients with
exertional angina developed ST-segment depression during
treadmill exercise testing, their P-selectin values were not
elevated relative to normal control subjects. These data
suggested that patients with ACS might have elevations in
circulating soluble P-selectin shortly after the onset of
symptoms. Shimomura et al. evaluated soluble P-selectin
levels in 16 patients with AMI, 15 patients with angina and
13 patients with chest pain syndromes but without coronary
artery disease (54). Samples were obtained at 7 AM the
morning after admission. Patients with AMI were found to
have increased soluble P-selectin relative to the other
groups, although nine of 16 AMI patients had P-selectin
levels below the highest values for both the control and
angina groups. These data suggest that P-selectin may not
adequately discriminate between patients with and without
AMI.
Risk stratification with P-selectin. The present study
examined the use of both soluble P-selectin and transmem-
Table 4. Predictive Properties of Creatine Kinase, MB Fraction (CK-MB) and P-Selectin for
Serious Cardiac Events At Time of Presentation
Assay Sensitivity Specificity
Positive
Predictive Value
Negative
Predictive Value
CK-MB 29% 91% 48% 82%
(17%–42%) (87%–96%) (32%–68%) (77%–87%)
Soluble P-selectin 35% 76% 28% 82%
(23%–49%) (71%–82%) (18%–39%) (77%–87%)
Membrane-bound
P-selectin
36% 72% 25% 81%
(24%–50%) (66%–79%) (16%–36%) (76%–87%)
P-selectin index (PSI) 56% 56% 24% 83%
(43%–70%) (49%–62%) (17%–32%) (77%–89%)
CK-MB and PSI 56% 56% 24% 83%
(43%–70%) (49%–62%) (17%–32%) (77%–89%)
The laboratory values were considered elevated for CK-MB $3.2 ng/dl, soluble P-selectin $138.8 ng/ml and membrane-bound
P-selectin $4.8%. These values were derived from receiver operator characteristic curve analysis at the time of presentation.
Numbers in parentheses are 95% confidence intervals.
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brane P-selectin for identification of patients with AMI,
ACS and serious cardiac events. We found that neither
soluble nor transmembrane P-selectin was useful for early
identification or risk stratification of patients who present to
the ED with acute chest pain syndromes. On the basis of
receiver operator curve analysis of the optimal cutoff for each
assay, the sensitivity and specificity for identification of
patients with AMI, ACS and serious cardiac events were
less than those for CK-MB. Use of the P-selectin index,
although theoretically attractive, did not appear to offer
additional benefits. The sensitivity of the P-selectin index
for AMI was not greater than that of CK-MB and the
specificity was less than that of CK-MB. For prediction of
ACS and serious cardiac events, the sensitivity of the
P-selectin index was greater than that of CK-MB but the
specificity was considerably less. This resulted in a positive
predictive value of only 39% for ACS and 24% for serious
cardiac events. Clearly, the low positive predictive values of
these assays prohibit initiation of any therapeutic interven-
tions with potentially harmful side effects (glycoprotein
IIb/IIIa inhibitors or fibrinolytic agents).
Potential explanations and limitations. There are several
potential explanations for our results. Our results differ from
prior studies, which mostly compared normal control sub-
jects with patients with AMI. The soluble P-selectin values
in the normal subjects were below those found in our
subjects who presented to the ED with chest pain syn-
dromes but were “ruled out” for ACS. It may be that our
population included a higher prevalence of patients with
hypertension, diabetes and underlying vascular disease than
the healthy control subjects used in prior studies. Our
patient population might have higher baseline levels of
platelet activation and higher mean P-selectin values than
those seen in healthy control subjects without ongoing chest
pain syndromes. In addition, platelet activation is a dynamic
process. Prior studies (36,54), in general, obtained serum
samples later in the course of disease. Our samples were
obtained at the time of ED presentation, which was
approximately 3 h after symptom onset and before any
treatment interventions. It is possible that later samples or
posttreatment samples may have higher levels of P-selectin.
It is important to address the possibility of selection and
misclassification bias in any study that evaluates early
identification and risk stratification of patients with ACS.
To reduce the likelihood of selection bias, we had trained
research assistants present in the ED 24 h per day, 7 days
per week during the study period. In conjunction with the
ED staff, they screened all ED patients to identify those
being evaluated for potential ACS. Statistical comparison of
the 29 patients excluded from the study with those who
consented for study enrollment found that they were similar.
Misclassification bias of important end points such as
AMI, unstable angina and serious cardiac events was re-
duced through daily follow-up on all study patients and
adherence to rigid definitions. All patients with a final
diagnosis of ACS had demonstration of underlying coro-
nary artery disease, positive findings on provocative testing
or myocardial marker evidence of AMI. However, it is
possible that some patients may have had false positive or
false negative stress tests, resulting in some misclassification
of unstable angina patients.
Many different processes and various clinical situations
readily influence platelets as sentinel markers of vessel wall
integrity. Their responsiveness can be measured by changes
in the expression of membrane glycoproteins including
P-selectin. It is interesting to note that Cannon et al.
observed that the platelets of patients with ACS have
increased reactivity to agonists as shown by flow cytometric
measurement of P-selectin expression when compared with
apparently healthy control subjects (55). This hypersensitiv-
ity to agonists among patients with ACS means that
extraordinary care must be taken to eliminate any causes of
ex vivo platelet activation. The effects of ex vivo platelet
activation would be greater on platelets from the subpopu-
lation of patients whose chest pain had its etiology in
coronary artery disease, because these patients have a lower
threshold for platelet activation. Opportunities for platelet
activation had to be minimized during the blood collection
and platelet and plasma assay preparation steps. Some of the
factors that are known to affect the P-selectin expression of
blood samples are the anticoagulant, shear caused by needle
gauge during venipuncture, residence time of unfixed blood
in a glass vacutainer tube and agitation or temperature
changes of blood after it is drawn and before fixation. These
variables were carefully controlled in this study. The anti-
coagulant of choice was CTAD (Diatube H, Becton/
Dickinson, Franklin Lakes, New Jersey, investigational use
only) which results in a lower percent of activated platelets
than acid-citrate-dexrose, disodium citrate, ethylenediami-
netetraacetic acid, and heparin. Venipuncture was per-
formed with a 19-ga needle to minimize the shear pro-
duced. The staining and fixation of platelets was initiated
within 1 h of the blood draw in accord with experimental
data showing the possibility of in vitro platelet activation in
blood sitting for greater than 60 min before the start of
staining and fixation. Vacutainers were carefully and gently
inverted to mix anticoagulant with blood. All samples were
stored in insulated carriers to assure constant temperature.
Because soluble P-selectin is in part produced by the proteo-
lytic cleavage of membrane-bound P-selectin, any variable that
causes the expression of P-selectin on the platelet surface can
also contribute to the plasma P-selectin levels. Therefore,
processing of plasma was carried out with the same rigor as that
observed for preparation of platelets for flow cytometric deter-
mination of membrane-bound P-selectin.
Conclusions. Our study of consecutive ED patients with
potential ACS found that neither soluble nor membrane-
bound P-selectin was useful for risk stratification of patients
for AMI, unstable angina or serious cardiac events.
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